Yang Wanli, Ma Jiaojiao, Zhou Wei, Cao Bo, Zhou Xin, Yang Zhiping, Zhang Hongwei, Zhao Qingchuan, Fan Daiming, Hong Liu
a State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases , Fourth Military Medical University , Xi'an , China.
b The First Brigade of Student , Fourth Military Medical University , Xi'an , China.
Expert Opin Ther Targets. 2017 Nov;21(11):1063-1075. doi: 10.1080/14728222.2017.1389900. Epub 2017 Oct 19.
Systemic chemotherapy is a curative approach to inhibit gastric cancer cells proliferation. Despite the great progress in anti-cancer treatment achieved during the last decades, drug resistance and treatment refractoriness still extensively persists. Recently, accumulating studies have highlighted the role of miRNAs in drug resistance of gastric cancers by modulating some drug resistance-related proteins and genes expression. Pre-clinical reports indicate that miRNAs might serve as ideal biomarkers and potential targets, thus holding great promise for developing targeted therapy and personalized treatment for the patients with gastric cancer. Areas covered: This review provide a comprehensive overview of the current advances of miRNAs and molecular mechanisms underlying miRNA-mediated drug resistance in gastric cancer. We particularly focus on the potential values of drug resistance-related miRNAs as biomarkers and novel targets in gastric cancer therapy and envisage the future research developments of these miRNAs and challenges in translating the new findings into clinical applications. Expert opinion: Although the concrete mechanisms of miRNAs in drug resistance of gastric cancer have not been fully clarified, miRNA may be a promising theranostic approach. Further studies are still needed to facilitate the clinical applications of miRNAs in drug resistant gastric cancer.
全身化疗是一种抑制胃癌细胞增殖的治疗方法。尽管在过去几十年抗癌治疗方面取得了巨大进展，但耐药性和治疗难治性仍然广泛存在。最近，越来越多的研究强调了微小RNA（miRNA）通过调节一些与耐药相关的蛋白质和基因表达在胃癌耐药中的作用。临床前报告表明，miRNA可能作为理想的生物标志物和潜在靶点，因此为胃癌患者开发靶向治疗和个性化治疗具有巨大潜力。涵盖领域：本综述全面概述了miRNA的当前进展以及miRNA介导的胃癌耐药的分子机制。我们特别关注与耐药相关的miRNA作为胃癌治疗中的生物标志物和新靶点的潜在价值，并展望这些miRNA的未来研究发展以及将新发现转化为临床应用所面临的挑战。专家观点：尽管miRNA在胃癌耐药中的具体机制尚未完全阐明，但miRNA可能是一种有前景的诊疗方法。仍需要进一步研究以促进miRNA在耐药性胃癌中的临床应用。
